Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Second, our model of care has proven effective in helping our patients lead healthier lives and reducing medical costs, reflecting in a net savings rate that is slightly ahead of our expectations |
| This reflects our expectation of continued growth in total medical spend and covered lives within our IKC programs, improved shared savings performance, and further fixed cost leverage, as outlined in Javier's earlier comments |
| External challenges of the past few years ultimately made us stronger, and with continued investment in our teammates, systems and capabilities, we believe that we're well-positioned for the years ahead |
| This is above our long-term expectation of 3% to 7% growth in adjusted operating income, driven by higher revenue per treatment growth in typical as a result of our investments in our revenue cycle management and cost savings in our non-labor patient care costs due to annualization of Mircera and footprint-related cost savings |
| We will continue to work hard to deliver strong results, innovate, and most importantly, provide a great clinical care for our patients |
| And so, we are extremely happy that at the end of the day, instead of spending the money on that, our teammates get the benefit of that |
| The remaining increase was driven equally by continued improvements in our revenue cycle management and typical fourth quarter seasonality related to higher acute mix and reimbursement for flu vaccines |
| Pito Chickering And then free cash flow conversion was very strong in '23, the guidance is about 54% in '24 |
| As the year progressed, we saw encouraging data points early in the year, which ultimately turned into consistent positive trends |
| These improved trends, combined with the strong operating performance and the positive impact on the initiatives we implemented, resulted in a 20% year-over-year growth in adjusted operating income, 28% growth in adjusted EPS and a return of our leverage ratio back to the target range |
| At the same time, we are able to produce four consecutive quarters with year-over-year growth in new patient admits |
| Our outperformance in the quarter relative to our expectations was primarily related to prior period development in our special needs programs in our IKC business, plus revenue per treatment growth from continued improvements in our revenue cycle management |
| Second, our labor performance in 2023 was better than 2022 |
| Our strong performance for the quarter puts us just above the top end of our updated full year guidance range from the Q3 call |
| Looking forward, improved retention and training costs represent an opportunity for improvement in the years ahead |
| Third, independent of these trends, we drove strong operating performance through our differentiated platform and capabilities |
| As we turn the page to 2024, we have a great opportunity to drive operating advancements that further differentiate DaVita within kidney care |
| Second, as noted, we're demonstrating progress in our IKC business and continue to expect breakeven by 2026 |
| First, 2024 adjusted operating income will benefit from the full year impact of positive development in 2023, including the annualization of revenue cycle improvement, our transition to Mircera and savings related to our center consolidation |
| This guidance demonstrates the resilience of our business and our ability, despite external challenges, to provide high-quality care while delivering strong financial results |
| That said, we're feeling pretty good about where our net savings came in, both on the SNP side and on the Medicare Advantage population within our value-based care |
| Our ability to invest in our people, process and systems, despite the operational and financial challenges of the last few years, has positioned us well for the years ahead |
| The result of these efforts is that we outperformed our 2023 adjusted operating loss forecast, and we believe we remain on track to deliver breakeven or better performance by 2026 |
| Within that portfolio, after many years of investment and consistent year-over-year improvements in cost savings, our MA contracts and special need plans have now reached profitability |
| '23 was a really impressive decline in DSOs |
| As we reflect on the past year, our 2023 financial performance highlighted the resilience of our business and revealed some of the early benefits of our multi-year investment in strengthening our platform |
| In 2023, our teammates logged over 42,000 hours of service to their communities, which marks our highest year ever in a step toward achieving our cumulative goal of 125,000 hours by 2025 |
| Full year 2023 adjusted operating income, adjusted EPS and free cash flow, all came in well-above our guidance from the beginning of the year |
| And finally, adjusted earnings per share will benefit from our share repurchase program, offset by other factors below the OI line, including other losses, higher interest expense and higher effective tax rate |
| Just in summary, we had a strong close to the year and that, combined with our guidance 2024, we are now back on a path to recuperate our pre-pandemic financial trajectory |
| Statement |
|---|
| International adjusted operating income was down $18 million quarter-over-quarter |
| In our IKC business, adjusted operating results were down $39 million sequentially, due primarily to timing of shared services revenue recognized in Q3 primarily from arrangements from 2022 |
| We began 2023 in an uncertain environment and shared the assumptions in our guidance that volume and labor challenges would continue throughout 2023 |
| So all these very expensive propositions and poor conduct have had an impact and the people do not want to open centers there |
| So, if you look at the '23 growth, which was effectively flat, that was burdened by the fact that the census declined over the course of 2022 and only started building in '23 |
| We entered 2023 with a 2% growth headwind due to the annualization of excess mortality from prior year |
| Since then, successive COVID surges have been weaker in magnitude with lower mortality |
| And I think that while there could be an unusual surprise because you never want to say that the chances are zero, highly, highly improbable that we didn't capture in our range, what is likely to play out |
| Below the OI line, we expect losses of approximately $60 million, largely as a result of our share of the losses in Mozarc, our co-investment with Medtronic in kidney products |
| Our non-GAAP number for 2023 is a loss of $94 million |
| So, we're guiding to a loss of $50 million for 2024 |
| So, if you take a more normal new to dialysis admit outlook and then a slightly negative mortality outlook, that's how we get to the 1% to 2% |
| For IKC, our guidance assumes an adjusted operating income loss of approximately $50 million |
| And as you know, last quarter, we had sort of a dissertation on GLP-1 that's gotten a lot of conversation |
| Looking at 2024 guidance, you're assuming a loss of $50 million in IKC |
| Pito Chickering So, you're taking a loss of $94 million after you back out the $25 million to $30 million |
| One is just structurally our CapEx is lower than our depreciation and amortization |
| The CKCC business is still new enough that we're not comfortable estimating the savings in the plan year |
| That said, we continue to be very mindful, and of course, work with the kidney community and disability groups, because it is sort of a dangerous risk out there that we want to make sure is not taken advantage of |
| And that's really a combination of a small census decline, which is not uncommon in Q4, offset by a better treatment mix day |
Please consider a small donation if you think this website provides you with relevant information